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Abstract Background: Bencycloquidium bromide (BCQB) is a novel, potent and se-
lective muscarinic M1/M3 receptor antagonist under development for the
treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of
BCQB in animals have been established in preclinical studies. However, no
clinical pharmacokinetic data are available for BCQB in humans.
Objective: The aim of this first-in-human study was to evaluate the pharma-
cokinetics, safety and tolerability of BCQB following single and multiple
intranasal doses in healthy Chinese subjects.
Methods: The clinical trial was comprised of the following four studies: (i) an
open-label, single-dose escalation study to evaluate the safety and tolerability
in healthy subjects after intranasal doses of BCQB ranging from 45 to 450 mg
(total of six doses); (ii) an open-label, multiple-dose escalation study to assess
the safety and tolerability in healthy subjects after intranasal administration
with 120 and 150 mg doses of BCQB (360 and 450mg/day) administered three
times daily for 15 days; (iii) a randomized, open-label and parallel-group
design to evaluate the single-dose pharmacokinetics of BCQB after intranasal
dosing (45, 90, and 180 mg); and (iv) ten subjects received 120mg of BCQB
by intranasal administration, three times daily for 5 days with a final single
dose on day 7 to assess its multiple-dose pharmacokinetics. Safety and tol-
erability of BCQB were evaluated by monitoring adverse events (AEs), ECG
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recordings, vital signs and clinical laboratory parameters. The pharmaco-
kinetic parameters for BCQB were calculated by software using non-
compartmental methods.
Results: All AEs were mild, of limited duration and no more frequent at
higher doses. There was no serious adverse event, death or withdrawal. No
clinically significant change was noted in clinical laboratory parameters,
cardiac parameters or vital signs. Following single intranasal dosing, BCQB
was rapidly absorbed with a median time to maximum concentration (tmax)
of 8 minutes for 45, 90, and 180mg dose groups; the plasma concentration
of BCQB decreased in a biphasic manner with the mean half-life (t½) of
8.5 hours; the maximum concentration (Cmax) and area under the plasma
concentration-time curve (AUC) of BCQB increased linearly across the
examined dose range of 45–180 mg. During the multiple dosing, the steady
state was achieved within 3 days of 120 mg three times daily dosing of BCQB.
A slightly greater AUCwas observed after 5 days of multiple dosing, with the
mean accumulation ratio of 1.26; however, the half-life was unchanged.
Conclusion: BCQB was safe and well tolerated in healthy Chinese subjects
when administered intranasally with single and multiple doses across the doses
studied. The mean Cmax and AUC increased proportionally to the studied
doses, and the steady state was achieved within 3 days after three times daily
dosing. A slight accumulation of BCQB following multiple dosing was ob-
served. The pharmacokinetics, safety and tolerability profiles of BCQB pose





[2, 2, 2] octane bromide (BCQB, figure 1), is a
novel selective muscarinic M1/M3 receptor an-
tagonist for the treatment of rhinorrhea in rhinitis
by intranasal administration. Rhinitis, an inflamma-
tion of the nasal mucous membrane, is one of the
most common diseases, and is estimated to affect
10–40% of the global population with increasing
prevalence in both children and adults.[1,2] Cur-
rently, ipratropium bromide (IB) is the only mus-
carinic antagonist in clinical use for the treatment
of rhinorrhea in rhinitis.[3] However, the anti-
cholinergic effect of IB is short-acting, and IB is
less selective among the M1, M2, and M3 mus-
carinic receptors.[4] Recently, long-term use of in-
haled IB has been shown to be associated with an
increased risk of adverse cardiovascular outcomes
in patients,[5] which may be related to its action on
the muscarinic M2 receptor in the heart. Given the
high prevalence of rhinitis and the undesirable
safety profile of IB, the development of addi-
tional options is clearly warranted. Many studies
have shown that intranasal BCQB has good effi-
cacy in the treatment of rhinitis especially rhi-
norrhea in preclinical studies.[6-10] Additionally,







Fig. 1. Chemical structure of bencycloquidium bromide.
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due to its high selectivity for the M1 and M3 re-
ceptors over the M2 receptor.[11,12] As a result,
M2 cardiac receptors are spared thereby reducing
the risks of cardiovascular adverse events.[13]
Preclinical toxicity studies also showed no appa-
rent change in the ECG or heart rate in dogs[13]
and rats.[14] Our recent phase II clinical trial in
China showed that intranasal administration of
BCQB was effective in reducing rhinorrhea with
few side effects. Preclinical studies described the
pharmacokinetics, tissue distribution, excretion
and metabolism of BCQB after intranasal dosing
in rats[15-18] or beagle dogs.[19] However, no data
are available on the pharmacokinetics, safety and
tolerability of BCQB in humans. Therefore, as a
first-in-human (FIH) clinical trial, this study was
conducted to evaluate the safety, tolerability and
pharmacokinetics of BCQB after single and multi-
ple intranasal doses in healthy Chinese subjects.
Methods
The FIH clinical trial was performed at a sin-
gle center (First Affiliated Hospital of Nanjing
Medical University) in Nanjing, China. The study
was approved by the Ethics Committee at this
study center and was conducted in accordance
with guidelines for the Declaration of Helsinki
and Good Clinical Practice (GCP) in China. All
subjects were informed of the investigational
nature of this study, and signed an informed
consent statement prior to the initiation of the
study.
Subjects
All eligible subjects were men or women aged
20–50 years, and were of Chinese origin (table I).
Subjects’ health states were analyzed on the basis
of medical history, physical examination, eye
examination, laboratory examination, and ECG.
The following exclusion criteria were applied
for subjects in this clinical trial: a history of clin-
ically significant cardiovascular, renal, urinary
tract, hepatic, pulmonary, gastrointestinal, eye,
mouth, nose, or mucosal diseases that might in-
terferewith absorption, distribution,metabolism, or
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or muscle disease, seizure disorder or a psychiatric
disorder that might hinder compliance with the
study; a history of known allergy or intolerance
to any drugs; a history of tobacco, alcohol or
drug abuse; those with abnormalities in clinical
laboratory parameters; those who had received
an investigational drug, or donation of blood in
the preceding 3 months, or had received any drug
within 2 weeks before the study start date, or was
considered by the investigator, for any reason, to
be an unsuitable candidate for receiving BCQB.
Females who were lactating or who had a positive
pregnancy test were also ineligible.
Study Drug and Administration
BCQB nasal sprays used in these studies were
manufactured by Beijing Shiqiao Biological and
Pharmaceutical Co. Ltd (Beijing, China). The in-
tranasal formulation provided different doses
(22.5, 45, 60, 75, 90, 135, 180, and 225mg) of BCQB
in a 0.09mL spray from a single-dose metered
sprayer. The same metered sprayer (0.09mL/spray)
with different drug loads was used in tolerability
and pharmacokinetic studies. For intranasal ad-
ministration, each subject received a single spray
in each nostril, for a total of two sprays. For ex-
ample, the dosage of 45mg was provided by a spray
of 22.5mg/spray in each nostril (22.5mg/spray· 2).
Prior to the administration of BCQB, the subject
gently blew his or her nose. A physician admin-
istered the nasal spray and attempted to concen-
trate the application on the lateral nasal wall,
particularly along the inferior and middle turbi-
nate mucosa, according to the standard operating
procedures (SOPs).
Study Design
Single-Dose Escalation Tolerability Study
An open-label, single-dose escalation design
was used to evaluate the safety and tolerability
of BCQB after intranasal dosing (see table II).
Subjects, 50% male and 50% female, were subse-
quently enrolled into the 45, 90, 180, 270, 360,
and 450 mg dose groups (6–8 subjects in each
Table II. Study design
Period Numbera Dose groups (mg)
Period 1b,c








Multiple-dose escalation tolerability study
8 120 tid for 14 days (360 mg/day)








10 120 tid for 5 days
a The number of subjects in each dose group.
b An open-label, dose escalation design was used.
c The trial would not proceed to the higher dose group until the safety and tolerability of the lower dose group were confirmed.
d The trial began with the 120mg dose group (360 mg/day), and this dosage was assigned according to the results of the single-dose
tolerability study.
e A randomized, open-label and parallel-group design was used.
f Administrated on day 1; received no treatment on day 2; and continued to receive the study drug tid from days 3 through 7.
tid = three times daily.
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group). The trial was designed to begin with the
45 mg dose group and would not proceed to the
higher dose group until the safety and tolerability
of the lower dose group was confirmed.
Multiple-Dose Escalation Tolerability Study
An open-label, multiple-dose escalation design
was performed to begin with the 120mg dose group
(360 mg/day) according to the results of the single-
dose tolerability study and would not proceed to
the higher dose group (450mg/day) until the safety
and tolerability of the 360 mg dose group was
confirmed (see table II). Subjects, 50% male and
50% female, were also subsequently enrolled into
two dose groups (eight subjects in each), and were
given 120 mg (360 mg/day) or 150 mg (450 mg/day)
of BCQB via nasal spray three times daily (at
7.30am, 12:00pm and 7:00pm) for 14 days to as-
sess its safety and tolerability.
Pharmacokinetic Study
A randomized, open-label and parallel-group
design was used to evaluate the pharmacokinetic
profile of BCQB after single intranasal dosing
(see table II). Thirty healthy subjects, 50% male
and 50% female, were randomized into 45, 90,
and 180 mg dose groups (ten subjects in each) for
the determination of the pharmacokinetic profile
of a single-dose BCQB by the investigator. An-
other ten subjects, 50% male and 50% female,
were administrated 120 mg of BCQB by intranasal
sprays on day 1; received no treatment on day 2;
and continued to receive the study drug three times
daily (at 7:30am, 12:00pm and 7:00pm) from days
3 through 7 to assess multiple-dose pharmaco-
kinetics (see table II).
The subjects were required to fast overnight
(12 hours) before administration, while standard
meals and water intake were provided 2 hours post-
dose. Blood samples (5mL) were collected at
0 hours (pre-dose), 2, 5, 10, 15, 30 minutes, 1, 2, 3,
5, 7, 12, 24, and 48 hours post-dose for the single-
dose study. For the multiple-dose study, blood
samples (5mL) were collected prior to dosing on
days 1, 5, 6, and 7 (0 hours prior to dosing) and 2,
5, 10, 15, 30 minutes, 1, 2, 3, 5, 7, 9, 12, 15, 24, and
36 hours post-dose on day 1 and day 7. Plasma
was separated and stored at -20C for analysis.
Urine samples were collected at 0 hours (pre-dose),
0–2, 2–4, 4–6, 6–8, 8–10, 10–12, 12–24, 24–36, and
36–48 hours post-dose for the single-dose study.
The total volume of urine in each time interval was
recorded and stored at -20C for analysis.
Safety Monitoring
Throughout the study, all subjects remained in
the study unit under continuous observation. De-
tails of adverse events (AEs) were obtained and
recorded by the study physicians. Routine safety
and tolerability were evaluated through AE re-
porting by the investigators and subjects, on the
basis of vital signs, physical examination, labor-
atory examination (routine blood, urine and feces
test, occult blood test and blood biochemical test)
and ECG, which were performed at scheduled
intervals during the studies. AEs that occurred dur-
ing the study were classified as mild (awareness of
a sign or symptom but comfortably tolerated),
moderate (discomfort that may interfere with daily
activities) or serious (death, life-threatening, re-
quiring hospitalization or incapacitating). AEs
were recorded and reported according to GCP.
Pharmacokinetic Measurement
The concentrations of BCQB in plasma and
urine were determined by validated liquid chro-
matography-mass spectrometry methods,[20,21]. The
lower limit of quantitation (LLOQ) of BCQB
in plasma was 5 pg/mL, while in urine it was
0.02ng/mL. The pharmacokinetic parameters were
calculated by WinNonlin Professional software
(Version 6.1, Pharsight Corporation, Mountain
View, CA, USA) using non-compartmental meth-
ods. The pharmacokinetic parameters in these
studies were maximum plasma concentration
(Cmax), the time to Cmax (tmax), the minimum
value of the steady-state plasma drug concen-
tration (Cmin,ss), elimination half-life (t½), the
area under the plasma concentration-time curve
(AUC) from time 0 to time t (AUCt), the AUC
from time 0 to infinity (AUC¥), the steady-state
AUC (AUCss), apparent clearance (CL/F), appar-
ent total volume of distribution (Vd/F), the average
steady-state concentration (Cav), the degree of
fluctuation (DF), the accumulation ratio (Rac)
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and the percentage of BCQB dose recovered in
urine (fe%).
Statistical Analysis
Statistical analysis was performed using SPSS
software version 11.0 (SPSS, Inc., Chicago, IL,
USA). Prior to analysis, dose-dependent param-
eters (Cmax and AUC) were determined using
natural logarithms of individual values. For the
exploration of dose proportionality, the slope b
and 90% confidence intervals (CIs) obtained from
the powermodel: ln(AUCorCmax)= a+ b· ln(dose)
were computed by analysis of covariance (AN-
COVA). The regression coefficient was significant
at level 0.1. The pre-defined criterion was set as
(0.500, 2.000),[22] and the criterion interval resulted
in the value of (0.500, 1.500). The differences in
pharmacokinetic parameters among dose groups
were compared using ANOVA except for tmax for
which the non-parametric test (NPT) was used.
Statistical comparisons between pharmacokinetic
parameters of single and multiple doses were per-
formed by the paired t-test (PTT), and the differ-
ences of pharmacokinetic parameters between
male and female subjects were compared by the
independent t-test (ITT). To determine whether
steady state was reached in the multiple-dose study,




Healthy males and females (n = 98) partici-
pated in the FIH studies. No subject dropped out
of the study. Baseline demographics of the study
population are presented in table I.
Single-Dose Pharmacokinetic Study
The mean plasma concentration-time curves
are shown in figure 2, and the main pharmaco-
kinetic parameters of BCQB are presented in
table III. Absorption of BCQB after intranasal
administration was rapid, with a median tmax of
8 minutes for 45, 90, and 180 mg doses, and the
plasma concentrations of BCQB decreased in a
biphasic manner, with the mean t½ of 8.5 hours
across the doses.
The mean and SD values of Cmax, AUCt and
AUC¥ versus dose relationships after single in-
tranasal dosing of BCQB are presented in figure 3.
Over the dose range studied, the mean Cmax,
AUCt andAUC¥ increased linearly across the doses
by linear regression analysis, with regression equa-
tions in figure 3. Dose proportionality was ob-
served (p > 0.05) by the ANOVA on the values of
ln(Cmax/dose) and ln(AUC/dose) among the three
dose groups. Moreover, the mean slopes of the
plots for ln(Cmax) or ln(AUC) versus ln(dose)
were all close to 1, and the 90% CIs of the slopes
were completely contained within the predefined
range (0.500, 1.500) for dose proportionality.
The mean slopes (90% CIs) were 1.067 (0.834,
1.300) for Cmax, 1.207 (0.921, 1.494) for AUCt, and
1.051 (0.762, 1.341) for AUC¥. Thus, Cmax and
AUC proved to be dose proportional across the
studied doses by different methods. The values
of tmax, t½, CL/F and fe% were independent of
dose (p > 0.05). There was no clinically significant
pharmacokinetic difference (p > 0.05, by ITT) be-
tween males and females in the single-dose study.
Multiple-Dose Pharmacokinetic Study
The mean plasma concentration-time curves of
BCQB after the first dose (day 1) and the last dose
(day 7) are presented in figure 4, and the pharma-
cokinetic parameters from the non-compartmental
analysis of measured plasma concentrations on
day 1 and day 7 are provided in table IV.
No significant difference in Cmin,ss was found
by ANOVA analysis, indicating that steady-state
conditions were achieved by day 5 after two con-
secutive three times daily 120 mg doses of BCQB.
Under steady-state conditions, BCQB was rap-
idly absorbed with the median tmax of 8 minutes
and a mean Cmax of 158.3 pg/mL, which were
identical to the single-dose parameters (day 1).
BCQB cleared from plasma in a biphasic manner
with no significant difference of t½ between the
first and the last dose. However, the mean AUC
values were higher in the multiple-dosing regimen
than the corresponding values obtained after single-
dose (day 1) administration (p < 0.01), and slight
22 Sun et al.
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accumulation was found following repeat dosing
of BCQB with Rac of 1.26 for AUCt (t = 5 hours).
A high DF of BCQB in plasma was achieved at
2.7 (t = 5 hours). Sex difference had no significant
influence on AUC, Cmax, tmax, and t½ between
the first and the last dose.
0
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Fig. 2. Mean plasma (a) and log-scaled mean plasma (b) concentration-time profiles of bencycloquidium bromide following single intranasal
doses in healthy Chinese subjects. The inset expands the first 3 hours of the profile. Data are presented as mean +SD (n = 10 per dose).
LLOQ = lower limit of quantitation.
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Safety and Tolerability
BCQB was safe and well tolerated when ad-
ministered as a single dose up to 450 mg and
multiple doses up to 150 mg three times daily
(450 mg/day) for 15 days. No death or serious
adverse events (SAEs) were reported during the
study and all subjects were in good compliance.
No notable mean change from baseline was re-
corded in the vital signs or clinical laboratory
variables. No individual participant value outside
the laboratory reference ranges was considered to
be clinically significant, and no clinically signif-
icant change in ECG and heart rate was reported
in any participant during the study.
Most subjects reported one or more AE. AEs
that occurred in two or more subjects, classified
according to the Medical Dictionary for Regu-
latory Activities system organ class and preferred
terms, are listed in table V. The most frequently
reported AEs were nasal irritation (including
nasal congestion, nasal dryness, redness of nasal
mucosa, and epistaxis) and mydriasis. However,
the nasal irritation was mild, of limited duration
and no inflammation was seen on early or follow-
up nasal examinations, while mydriasis was also
mild, of limited duration and of no clinical sig-
nificance. Overall, all the AEs reported were mild
in intensity, expected, based on the known ac-
tivity of the drug or the intranasal route of ad-
ministration, and not considered to be clinically
significant. There was no trend for increasing
AEs with increasing doses over the dose range
evaluated.
Table III. Main pharmacokinetic parameters of bencycloquidium
bromide in healthy Chinese subjects after single intranasal doses 45,
90, and 180 mga
Parameters Dose (mg)
45 (n =10) 90 (n = 10) 180 (n= 10)
Cmax (pg/mL) 110.4 –52.5 170.6 – 63.4 432.1 –93.9
tmax (min) 8 (2–15) 8 (5–30) 8 (5–15)
t½ (h) 7.4 –5.5 7.5 – 6.8 10.7 –5.3
AUCt (ngh/L) 159.5 –104.6 338.6 – 174.6 743.0 –264.0
AUC¥ (ngh/L) 218.6 –137.6 415.7 – 258.2 831.3 –291.4
CL/F (L/h) 298.3 –228.3 285.8 – 139.1 243.8 –90.2
Vd/F (L) 2218 – 863 2161 –1097 3438– 1202
fe% 4.5 –2.3 4.6 – 2.1 3.6 –1.6
a Data are presented as mean –SD except for tmax, which was
expressed as median (range).
AUC¥ = area under the concentration-time curve from time 0 to
infinity; AUCt=AUC from time 0 to time t; CL/F =apparent total body
clearance; Cmax =maximum concentration; fe% = the cumulative
percentage of bencycloquidium bromide excreted in urine; t½ =half-





































 = 4.654 × dose − 5.100
R2 = 1.0000























Fig. 3. Mean value (– SD) dose profiles of bencycloquidium bro-
mide (BCQB) following single intranasal doses of BCQB 45, 90, and
180 mg (n= 10 per dose). (a) AUCt; (b) AUC¥; (c) Cmax. Linear re-
gression is shown in the figure. AUCt=AUC from time 0 to time t;
AUC¥=AUC from time 0 to infinity; Cmax =maximum concentration.
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Discussion
At present, the anticholinergic medications
used in the treatment of airway diseases are
not selective for muscarinic receptor subtypes.[23]
The novel selective muscarinic M1/M3 receptor
antagonists, such as aclidinium bromide[24] and
penehyclidine hydrochloride,[25,26] are under de-
velopment for the therapy of chronic obstructive
pulmonary disease (COPD), while the novel agents
under development for the treatment of rhinor-
rhea in rhinitis are limited. BCQB is under devel-
opment not only for the treatment of rhinorrhea in
rhinitis but also for the therapy of COPD.[7,11] The
aerosol with quantitative inhalation of bencyclo-
quidium bromide[27] is under development.
The objective of this FIH study was to assess
the pharmacokinetics, safety and tolerability after
single and multiple intranasal doses of BCQB in
healthy Chinese subjects. Following single intra-
nasal doses in healthy Chinese adult subjects,
BCQB was rapidly absorbed, the plasma concen-
tration of BCQB decreased in a biphasic manner,
the Cmax and AUC of BCQB increased in pro-
portion to the studied doses, and the mean t½
and the mean CL/F were independent of the
administered doses. The mean t½ of the studied
dose groups ranged from 7.4 to 10.7 hours. The
small difference of t½ observed was due to assay
0
































Fig. 4. Mean plasma concentration-time profiles of bencycloquidium bromide on day 1 and day 7 following multiple intranasal doses in healthy
Chinese subjects, respectively. The inset expands the first 3 hours of the profile. Data are presented as mean –SD (n= 10 per dose).
Table IV. Main pharmacokinetic parameters of bencycloquidium
bromide in healthy Chinese subjects after multiple intranasal ad-
ministration of 120mg, with single administration on day 1; received
no treatment on day 2; and continued to receive the study drug three




120 mg (n =10)
AUCt (ngh/L) 334.9 –127.0 551.4 – 255.4
AUC¥ (ngh/L) 430.0 –183.6 662.2 – 278.7
tmax (min) 8 (2, 30) 8 (2, 30)
t½ (h) 11.0 –9.5 12.3 – 4.2
Cmax (pg/mL) 175.4 –77.2 158.3 – 77.8
Css,min (pg/mL) 16.12 – 8.49
Cav (pg/mL) 63.76 – 24.78
DF 2.7 – 0.9
Rac 1.26 – 0.39
a Data are presented as mean –SD except for tmax, which was
expressed as median (range).
AUCt=area under the concentration-time curve from time 0 to time t;
AUC¥=AUC from time 0 to infinity; Cav= the average steady-state
concentration; Cmax=maximum concentration; Css,min= the minimum
value of the steady-state plasma drug concentration; DF= the degree of
fluctuation;Rac= the accumulation ratio; t½= half-life; tmax= time to Cmax.
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limitations in the determination of the BCQB
concentration in the terminal phase of the concen-
tration-time curve, where plasma concentrations of
BCQB at sampling times in the latter part of the
concentration-time curve were below the LLOQ
(5pg/mL) for many subjects, particularly at lower
doses (figure 2). However, no statistical significance
(p> 0.05) in t½ was found among the studied dose
groups. The duration of action of 50% of BCQB
(t½, off-set) in classical bioassays was approx-
imately 3 hours,[11] which was shorter than the ter-
minal t½ of BCQB in plasma. It may be due to the
fact that the terminal t½ in plasma is reflective of the
rate of drug elimination from the body but not
reflective of the duration of drug action.
In the multiple-dose study, the steady-state
concentration was achieved within 3 days of con-
secutive dosing and the pharmacokinetic param-
eters of BCQB were similar to those following
single dose except AUC. A slight accumulation
was noted with the mean Rac of 1.26 based on
AUCt, but the slight accumulation resulted in sus-
tained plasma exposure upon daily dosing. A high
DF for BCQB concentration in plasma was ob-
served, for the concentrations of BCQB in plasma
declined rapidly from tmax to t.
Wide inter-subject variability in pharmacokinetic
parameters was reflected in their SD (tables III
and IV), but the reasons were not clear. There
are several factors that can lead to the variability
of pharmacokinetic parameters. First, although
physicians administered BCQB carefully accord-
ing to the SOPs, the intranasal administration
process may cause variability. For example, while
intranasal doses were administered to the lateral
nasal wall, the influence of factors (such as pos-
ture, position of the head, and nasal mucosal blood
flow) could increase the variability of pharmaco-
kinetic parameters. Second, the presence of nasal
mucosal physiology and pathology is another
potential source of variability.[28] For example,
hyperemia would be expected to influence drug
absorption after intranasal application, for the
hyperemia can change the penetration of nasal
mucosa, which may influence drug absorption.
Third, only ten subjects had been studied for the
pharmacokinetic profile in each group and the
variability in one or more individual would affect
Table V. Treatment-emergent adverse events occurring in two or more subjects (safety population, n = 58)
Treatment-emergent adverse events Safety assessment
Single dose (mg) Multiple doses (mg)
45 90 180 270 360 450 Total 120 150 Total
n 6 8 8 8 6 6 42 8 8 16
Upper respiratory
Nasal dryness 4 2 0 2 0 4 12 5 3 8
Nasal congestion 4 3 3 0 4 1 15 6 4 10
Epistaxis 2 0 0 0 0 0 2 1 0 1
Color of nasal mucosa (red) 3 1 3 0 0 0 7 0 0 0
Color of nasal mucosa (pale) 0 0 0 1 0 1 2 0 0 0
Other nasal symptoms 0 0 0 0 0 3 3 1 0 1
Neurology
Headache 1 0 0 0 0 0 1 1 0 1
Dizziness 2 1 0 0 0 0 3 0 0 0
Drowsiness 0 0 0 0 0 0 0 2 0 2
Ocular
Ocular hypertension 0 0 1 0 0 0 1 1 0 1
Mydriasis 0 2 1 1 3 1 8 5 4 9
Gastrointestinal
Dry mouth 0 0 0 2 0 0 2 0 0 0
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the overall results greatly. Future clinical studies
should also seek to identify the factors respon-
sible for variability in intranasal dose delivery,
deposition and mucosa absorption in order to
optimize the safety profile of BCQB that could
often be required for long-term therapy.
In this FIH study, repeated administration of
BCQB did not lead to any cardiovascular adverse
event in healthy subjects, consistent with previously
published results in animals.[13,14] However, fu-
ture investigations to evaluate the effect of long-
term doses of BCQB on the nasal mucosa, ECG
and heart rate are warranted.
Conclusion
BCQB was safe and well tolerated in this FIH
study. No SAEs occurred, no change of ECG and
heart rate was observed, and all subjects were in
good compliance. The mean Cmax and AUC of
BCQB were proportional to the studied doses,
and the steady state was achieved within 3 days.
A slight accumulation following 5 days of 120 mg
three times daily dosing of BCQB was observed,
but the elimination rate showed no change. On
the basis of this study in healthy subjects, BCQB
is worthy of further investigation for treating
rhinorrhea in rhinitis.
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